Biomarkers for antiepileptic drug response

Biomarkers in Medicine

Volumn 5, Issue 5, 2011, Pages 635-641

  Glauser, Tracy A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

1502 MDR1; 3101 HLAB; ABCB1; antiepileptic drug; biomarkers; CYP2C19; CYP2C9; HLAA; multidrug resistance gene 1; PGY1; pharmacogenetics

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID CARRIER; ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; CARBAMAZEPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DIAZEPAM; HLA A ANTIGEN; HLA B ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; NORDAZEPAM; PHENOBARBITAL; PHENYTOIN; SEROTONIN TRANSPORTER; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.3; VIGABATRIN;

ALLELE; ARTICLE; ASIAN; CYP2C19 GENE; CYP2C9 GENE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG METABOLIZING GENE; DRUG RESPONSE; DRUG TRANSPORTER GENE; EPILEPSY; GENE; GENETIC POLYMORPHISM; GENOTYPE; HLA GENE; HUMAN; LINKAGE ANALYSIS; MEDICAL RESEARCH; METHODOLOGY; MULTIDRUG RESISTANCE GENE 1; PATIENT CARE; PHARMACOGENETICS; PREDICTION; RELIABILITY; SCN1A GENE; SCN2A GENE; SCN3A GENE; SINGLE DRUG DOSE; SODIUM CHANNEL GENE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VISUAL IMPAIRMENT;

ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; CARBAMAZEPINE; EPILEPSY; HLA-A ANTIGENS; HLA-B15 ANTIGEN; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 80054806990     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.75     Document Type: Article

References (62)

1. Loddenkemper T, Glauser T, Morita D. Pharmacogenetics of antiepileptic medications. In:Wyllies Treatment of Epilepsy: Principles and Practice . Wyllie E, Gupta A, Lachhwani D (Eds). Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, PA, USA (2011).
2. Glauser TA. Monitoring gene changes during antiepileptic drug therapy to widen the safety window and reduce pharmacoresistance. Epilepsia 48(Suppl. 1), 19-25 (2007). (Pubitemid 46280515)
3. Dodson WE. Pharmacokinetic principles of antiepileptic therapy in children. In:Pediatric Epilepsy: Diagnosis and Therapy . Pellock JM, Dodson WE, Bourgeois BFD (Eds). Demos Medical Publishing, Inc., New York, NY, USA (2001).
4. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin. Genet. 56(4), 247-258 (1999).
5. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and individualized drug therapy: high expectations and disappointing achievements. Am. J. Pharmacogenomics 3(6), 361-370 (2003). (Pubitemid 38044275)
6. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 26(1), 51-78 (2007). (Pubitemid 46051813)
7. Locharernkul C, Shotelersuk V, Hirankarn N. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions. J. Clin. Neurosci. 18(10), 1289-1294 (2011).
8. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens- Johnson syndrome. Nature 428(6982), 486 (2004).
9. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008).
10. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11(3), 349-356 (2010).
11. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348(15), 1442-1448 (2003). (Pubitemid 36407173)
12. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50(1), 1-23 (2009).
13. Zimprich F, Sunder-Plassmann R, Stogmann E, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63(6), 1087-1089 (2004). (Pubitemid 39287922)
14. Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther. Drug Monit. 29(3), 305-312 (2007). (Pubitemid 47262260)
15. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 8(9), 1151-1158 (2007).
16. Seo T, Ishitsu T, Ueda N, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7(4), 551-561 (2006). (Pubitemid 43891412)
17. Kwan P, Baum L, Wong V, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 11(1), 112-117 (2007). (Pubitemid 47087203)
18. Soranzo N, Cavalleri GL, Weale ME, et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res. 14(7), 1333-1344 (2004). (Pubitemid 39029230)
19. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6(4), 411-417 (2005). (Pubitemid 40916364)
20. Tan NC, Heron SE, Scheffer IE, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63(6), 1090-1092 (2004). (Pubitemid 39287923)
21. Sills GJ, Mohanraj R, Butler E, et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46(5), 643-647 (2005). (Pubitemid 40628658)
22. Kim DW, Kim M, Lee SK, Kang R, Lee SY. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15(5), 344-347 (2006). (Pubitemid 43812238)
23. Kim YO, Kim MK, Woo YJ, et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 15(1), 67-72 (2006). (Pubitemid 43092098)
24. Leschziner G, Jorgensen AL, Andrew T, et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol. 5(8), 668-676 (2006). (Pubitemid 44062410)
25. Ozgon GO, Bebek N, Gul G, Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur. Neurol. 59(1-2), 67-70 (2008). (Pubitemid 350277263)
26. Shahwan A, Murphy K, Doherty C, et al. The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 73(2), 192-198 (2007). (Pubitemid 46331873)
27. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-interindividual and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 50(4), 898-903 (2009).
28. Kim DW, Lee SK, Chu K, et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res. 84(1), 86-90 (2009).
29. Grover S, Bala K, Sharma S, et al. Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie 92(9), 1207-1212 (2010).
30. Alpman A, Ozkinay F, Tekgul H, et al. Multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug-resistant epilepsy. J. Child Neurol. 25(12), 1485-1490 (2010).
31. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW. Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol. Biomarkers Prev. 10(12), 1307-1308 (2001). (Pubitemid 34027766)
32. Dickinson R, Hooper W, Patterson M, Eadia M, Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther. Drug Monit. 7, 283-289 (1985). (Pubitemid 15228334)
33. Yasumori T, Chen LS, Li QH, et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem. Pharmacol. 57(11), 1297-1303 (1999). (Pubitemid 29185151)
34. Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 62(3), 287-292 (1997). (Pubitemid 27417794)
35. Mamiya K, Ieiri I, Shimamoto J, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39(12), 1317-1323 (1998). (Pubitemid 29005631)
36. Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48(3), 409-415 (1999). (Pubitemid 29417726)
37. Van Der Weide J, Steijns LS, Van Weelden MJ, De Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11(4), 287-291 (2001). (Pubitemid 32537401)
38. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther. Drug Monit. 22(2), 230-232 (2000). (Pubitemid 30196831)
39. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 70(4), 391-394 (2001). (Pubitemid 33022480)
40. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52(4), 349-355 (2001). (Pubitemid 32939439)
41. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 36(Suppl. 5), S8-S13 (1995).
42. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin. Pharmacokinet. 46(4), 271-279 (2007). (Pubitemid 46507006)
43. Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1(3), 204-210 (2001).
44. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur. J. Clin. Pharmacol. 55(11-12), 821-825 (2000). (Pubitemid 30201764)
45. Hadama A, Ieiri I, Morita T, et al. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. Ther. Drug Monit. 23(2), 115-118 (2001). (Pubitemid 32240137)
46. Whyte MP, Dekaban AS. Metabolic fate of phenobarbital. A quantitative study of p-hydroxyphenobarbital elimination in man. Drug Metab. Dispos. 5(1), 63-70 (1977). (Pubitemid 8040983)
47. Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low KM diazepam N-demethylases. Drug Metab. Dispos. 25(2), 133-139 (1997). (Pubitemid 27086112)
48. Qin XP, Xie HG, Wang W, et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin. Pharmacol. Ther. 66(6), 642-646 (1999). (Pubitemid 30014093)
49. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102(15), 5507-5512 (2005). (Pubitemid 40530288)
50. Heinzen EL, Yoon W, Tate SK, et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80(5), 876-883 (2007). (Pubitemid 46668456)
51. Tate SK, Singh R, Hung CC, et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16(10), 721-726 (2006). (Pubitemid 44454866)
52. Zimprich F, Stogmann E, Bonelli S, et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 49(6), 1108-1109 (2008). (Pubitemid 351794005)
53. Kwan P, Poon WS, Ng HK, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet. Genomics 18(11), 989-998 (2008).
54. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011).
55. Lee AY, Kim MJ, Chey WY, Choi J, Kim BG. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur. J. Clin. Pharmacol. 60(3), 155-159 (2004). (Pubitemid 38757125)
56. Kinirons P, Cavalleri GL, Singh R, et al. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res. 70(2-3), 144-152 (2006). (Pubitemid 44189176)
57. Hecimovic H, Stefulj J, Cicin-Sain L, Demarin V, Jernej B. Association of serotonin transporter promoter (5-HTTLPR) and intron 2 (VNTR-2) polymorphisms with treatment response in temporal lobe epilepsy. Epilepsy Res. 91(1), 35-38 (2010).
58. Ferraro TN, Dlugos DJ, Buono RJ. Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. Pharmacogenomics 7(1), 89-103 (2006).
59. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6), 1069-1077 (2010).
60. US Department of Health and Human Services, US FDA. Guidance for Industry Pharmacogenomic Data Submissions. www.fda.gov/downloads/ RegulatoryInformation/ Guidances/ ucm126957.pdf (Accessed 8 August 2011)).
61. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.cypalleles.ki.se (Accessed 8 August 2011)).
62. Phenytoin product label www.pharmgkb.org/clinical/7438353.pdf (Accessed 28 August 2011)).